Latest:
Dr. Parikh on Future Research Directions in Hepatitis C-Related HCC
Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Neeta Somaiah, MD
Neeta Somaiah, MD, is a professor and department chair of the Department of Sarcoma Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Latest:
Dr Somaiah on Mutation-Specific Therapy in Gastrointestinal Stromal Tumors
Neeta Somaiah, MD, discusses the landscape of mutation-specific therapy for the treatment of patients with a gastrointestinal stromal tumor.
Neil Horowitz, MD
Latest:
Dr. Horowitz on Frontline Strategies in Newly Diagnosed Ovarian Cancer
Neil Horowitz, MD, director of Clinical Research in Gynecologic Oncology, assistant professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline strategies in the treatment of patients with newly diagnosed advanced ovarian cancer.
Neil L. Berinstein, MD
Latest:
Dr. Berinstein on Combination Treatments for High-Risk and Recurrent Follicular Lymphoma
Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.
Neil P. Shah, MD, PhD
Latest:
Dr. Shah on TKI Treatment Discontinuation in CML
Neil P. Shah, MD, PhD, professor of medicine, Division of Hematology and Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses TKI treatment discontinuation in patients with chronic myeloid leukemia.
Neil S. Wenger, MD, MPH
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors
For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Neil Steers, PhD
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors
For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.